Feasibility of a novel mixed-nutrient supplement in a multimodal prehabilitation intervention for lung cancer patients awaiting surgery: A randomized controlled pilot trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

To investigate, in lung cancer patients awaiting elective surgery, the feasibility of delivering a novel four-week multimodal prehabilitation intervention and its effects on preoperative functional capacity and health-related quality of life (HRQoL), compared to standard hospital care.

Who Took Part

By PubMed's age tags, the people studied were older adults.

Adult patients awaiting elective thoracotomy for lung cancer stages I, II or IIIa, were approached to participate in an open-label, randomized controlled trial of two parallel arms: multimodal prehabilitation combining a mixed-nutrient supplement with structured supervised and home-based exercise training, and relaxation-strategies (Prehab) or standard hospital care (Control).

Feasibility was assessed based on recruitment and adherence rates to the intervention and study outcome assessment.

How the Study Was Run

The design is described as randomized, open-label, parallel-group and pilot.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Being open-label, the Copper (Supplement) study did not mask who received what.

The Copper (Supplement) group and the comparison group ran side by side rather than switching.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

What Was Measured

The subject headings attached to it are COVID-19, Exercise Therapy, Feasibility Studies, Lung Neoplasms, Nutrients, Nutritional Support and Pandemics.

The authors tagged it with the keywords Nutrition and exercise, Prehab, Preoperative and Six-minute walk test.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Copper (Supplement).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (International journal of surgery (London, England)), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.